摘要
目的探讨薏苡附子败酱散联合美沙拉嗪对溃疡性结肠炎患者的临床疗效。方法 106例患者随机分为对照组和观察组,每组53例,对照组给予美沙拉嗪,观察组在对照组基础上加用薏苡附子败酱散,疗程4周。然后,检测临床疗效、炎症因子[肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)、白介素-8(IL-8)]、肠道菌群(大肠杆菌、肠球菌、乳酸杆菌、双歧杆菌)、炎症性肠病生存质量问卷(IBDQ)评分变化。结果观察组总有效率显著高于对照组(P<0.05)。治疗后,2组炎性因子水平显著降低(P<0.05),IBDQ评分显著升高(P<0.05),以观察组更明显(P<0.05);观察组双歧杆菌、乳酸杆菌数量显著增加(P<0.05),大肠杆菌、肠球菌数量显著减少(P<0.05)。2组不良反应少而轻微。结论薏苡附子败酱散联合美沙拉嗪能下调溃疡性结肠炎患者血清炎症因子水平,纠正肠道菌群失调,提高生活质量,耐受性良好。
AIM To explore the clinical effects of Yiyi Fuzi Baijiang Powder combined with mesalazine on patients with ulcerative colitis. METHODS One hundred and six patients were randomly assigned into control group(53 cases) for 4-week administration of mesalazine, and observation group(53 cases) for 4-week administration of both Yiyi Fuzi Baijiang Powder and mesalazine. Subsequently, the changes in clinical efficacy, inflammatory factors[tumor necrosis factor-α(TNF-α), interleukin-6(IL-6), interleukin-8(IL-8)], intestinal flora(Escherichiacoli, Enterococcus, Lactobacillus, bifidobacteria) and inflammatory bowel disease questionnaire(IBDQ) score were detected. RESULTS The observation group demonstrated significantly higher total effective rate than the control group(P<0.05). After the treatment, the two groups displayed markedly reduced inflammatory factor levels(P<0.05) and elevated IBDQ score(P<0.05), especially for the observation group(P<0.05), and the observation group exhibited obviously increased bifidobacteria, Lactobacillus counts(P<0.05) and decreased Escherichia coli, Enterococcus counts(P<0.05). Few and slight adverse reactions were found in the two groups. CONCLUSION For the patients with ulcerative colitis, Yiyi Fuzi Baijiang Powder combined with mesalazine can down-regulate serum inflammatory factor levels, correct intestinal flora imbalance and improve life quality with good tolerance.
作者
张双喜
宋晓锋
张相安
安永康
ZHANG Shuang xi;SONG Xiao feng;ZHANG Xiang an;AN Yong kang(The First Affiliated Hospital of Henan University of Chinese Medicine,Zhengzhou 450000,China;Xuchang Central Hospital,Xuchang 461000,China)
出处
《中成药》
CAS
CSCD
北大核心
2019年第11期2642-2646,共5页
Chinese Traditional Patent Medicine
基金
河南省中医管理局科学研究专项项目(2017ZY2058)
河南省中医药科学研究专项课题(2018ZY2083)
作者简介
张双喜(1979—),男,博士,副主任医师,从事中医肛肠疾病研究。Tel:(0371)66200302,E mail:doctor6019@sina.com。
